Table 4.
Adverse events of the lenvatinib combined nivolumab group
| Adverse events | Grade 1/2 | Grade 3/4 | All grades |
|---|---|---|---|
| Dermatitis | 20.0% | 15.0% | 35.0% |
| Pruritus | 27.5% | 0.0% | 27.5% |
| Fatigue | 20.0% | 0.0% | 20.0% |
| Hypertension | 15.0% | 5.0% | 20.0% |
| Diarrhea | 17.5% | 0.0% | 17.5% |
| Dysphonia | 12.5% | 0.0% | 12.5% |
| Stomatitis | 10.0% | 2.5% | 12.5% |
| GI bleeding | 0.0% | 7.5% | 7.5% |
| Pneumonitis | 5.0% | 2.5% | 2.5% |
| HRSR | 5.0% | 0.0% | 5.0% |
| Laboratory test | |||
| Hypothyroidism | 27.5% | 0.0% | 27.5% |
| Proteinuria | 20.0% | 0.0% | 20.0% |
| Neutropenia | 17.5% | 0.0% | 17.5% |
| Thrombocytopenia | 15.0% | 0.0% | 15.0% |
| Anemia | 10.0% | 0.0% | 10.0% |
| SAE* | 0.0% | 10.0% | 10.0% |
HRSR hand-foot skin reaction, SAE severe adverse event
*2 gastric intestinal bleeding, 1 duodenal perforation, 1 pneumonitis